news
Improving ovarian cancer outcomes with artificial intelligence
Researchers have developed an AI based model that is 80 percent accurate in predicting the therapy outcome of high-grade ovarian cancer.
List view / Grid view
Informatics
news
Chemotherapy success calculated by new machine learning model
Percent necrosis calculated with machine learning model for patients with osteosarcoma provides an accurate prognosis for survival.
podcasts
Episode 23 – Making organoids ready for screening
Tune into this podcast to understand why researchers are turning to 3D Organoids and how organoids can be made ready for screening.
webinar
Unlocking protein potential: liquid handling solutions for drug discovery
29 September 2023 | By Analytik Jena
Watch this webinar to learn how PROTACs are revolutionising drug discovery, and the critical role protein purification plays in the production of therapeutic proteins.
whitepaper
ebook: Maximizing preclinical confidence in target efficacy and safety
This ebook outlines Euretos’ approach to target discovery and indication expansion. Whilst also discussing data-driven target selection.
article
Drug Target Review – Issue 3 2023
A new Drug Target Review issue is now ready to download! This issue features articles on vaccine development, artificial intelligence and organoids.
webinar
Turning Plans into Reality: Real Examples of Custom Automation Projects
24 August 2023 | By Bio-Rad Laboratories Inc.
Watch our industry experts to learn about the tangible benefits and best practice of custom flow cytometry automation projects. You’ll discover how to reduce your challenges implementing tailored automation, controlling the quality of the data produced and improving the reliability of your data acquisition.
news
Artificial intelligence cell analysis for swift blood disease diagnosis
Researchers from the German Cancer Research Center (DKFZ) and the Cambridge Stem Cell Institute have developed an artificial intelligence (AI) system capable of identifying and characterising white and red blood cells within microscopic images of blood samples. This AI algorithm holds the potential to aid medical professionals in diagnosing blood…
news
New computational tool may fuel vaccine development
La Jolla biologists harness machine learning and computational tools to make sense of immune system data.
podcasts
Episode 20- Regulations on artificial intelligence- impact on drug discovery
Tune in to this episode to hear experts discussing the hot topic that is AI and how AI technology is used in drug discovery, looking specifically at how Biotechs & Pharma are trying to keep up with emerging technology.
news
Harnessing machine learning for early cancer detection in primary care
Machine learning (ML) presents a promising opportunity to revolutionize early cancer detection in primary care, addressing the challenges associated with diagnostic errors and improving patient outcomes. The potential of ML in this field is highlighted in a recent paper published in Oncoscience
article
Navigating the challenges and opportunities of AI in drug development and personalised medicine
This article is the second part of Drug Target Review’s Izzy Wood’s discussion with Olivia Cavlan, Chief Corporate Development and Strategy Officer at Alchemab Therapeutics Ltd, exploring the role of AI in target discovery, its applications in personalised medicine, and the evolving landscape of pharmaceutical development.
article
Unleashing the power of AI in target discovery and resilience against disease
In this interview Drug Target Review’s Izzy Wood and Olivia Cavlan, Chief Corporate Development and Strategy Officer at Alchemab Therapeutics Ltd, uncover the untapped potential of AI in target discovery. Alchemab’s revolutionary platform aims to identify common antibodies in resilient individuals and uncover the antigens that contribute to their disease-fighting…
article
Drug Target Review – Issue 2 2023
A new Drug Target Review issue is now ready to download! This issue features articles on cell and gene therapy, imaging and screening.
video
Video: Four integrated technologies for biologics developability assessment
The decisions you make about your biologics candidates early in the pipeline ultimately affect their success as therapeutics. Combine sizing and stability information to develop successful biologics.